Labour analgesia - A risk-benefit analysis

被引:14
|
作者
Eberle, RL [1 ]
Norris, MC [1 ]
机构
[1] ALBANY MED COLL, DEPT ANESTHESIOL, ALBANY, NY USA
关键词
D O I
10.2165/00002018-199614040-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The pain associated with labour can be severe. The ideal labour analgesic does not exist and systemic opioids provide little relief. Nausea, vomiting and sedation are common adverse effects of systemic opioids. Paracervical block can relieve only the pain of the first stage of labour. The duration of analgesia obtained using paracervical block is limited and repeat blocks increase the risk of direct fetal injection. Epidural analgesia effectively relieves labour pain. The insertion of an epi dural catheter can provide continuous analgesia throughout labour. In addition, the catheter can be used to provide surgical anaesthesia, should operative delivery be required. Epidural local anaesthetics commonly produce maternal hypotension and motor blockade. However, opioids potentiate the effect of epidural local anaesthetics. Thus, concomitant epidural opioid injection allows the use of lower concentrations of local anaesthetics, decreasing the frequency and severity of hypotension and motor blockade. Epidural analgesia has other, potentially catastrophic, adverse effects but, with safe clinical practice, these problems are extremely rare. Intrathecal injection of opioids or local anaesthetics also provides effective labour analgesia. However, no single intrathecal drug or drug combination reliably provides analgesia for the duration of labour. Many clinicians use both intrathecal and epidural analgesia as a combined spinal-epidural technique. This approach provides the rapid onset of intrathecal drugs and the flexibility of continuous epidural block. Fetal heart rate decelerations occasionally follow the use of any of the above labour analgesic techniques. Most studies of the aetiology of fetal heart rate decelerations have focused on factors unique to each analgesic technique. However, the similar timing and appearance of fetal bradycardia suggests a common cause. Induction of maternal analgesia may transiently alter the balance between factors encouraging and inhibiting uterine contraction. A temporary increase in the uterotonic effects of endogenous or exogenous oxytocin may then produce a tetanic uterine contraction with subsequent decrease fetal oxygen delivery and resultant fetal bradycardia. Regardless of aetiology, these bradycardias are transient and should not produce maternal or fetal morbidity. Much controversy surrounds the effects of analgesia, especially epidural block, on the course and outcome of labour. Various studies have reported that epidural analgesia slows labour, increases the incidence of malposition of the fetal head, increases the need for forceps delivery and increases the risk of caesarean delivery. Most of the studies reporting these effects are retrospective and nonrandomised. More careful studies suggest that specific anaesthetic techniques (i.e. local anaesthetic-opioid mixtures) or obstetrical management can limit or eliminate these 'risks' of epidural labour analgesia.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 50 条
  • [1] Preliminary Risk-Benefit Analysis of Ropivacaine in Labour and Following Surgery
    Ingemar Cederholm
    [J]. Drug Safety, 1997, 16 : 391 - 402
  • [2] A Risk-Benefit Assessment of Therapies for Premature Labour
    Kenneth Higby
    Cheryl R. Suiter
    [J]. Drug Safety, 1999, 21 : 35 - 56
  • [3] A risk-benefit assessment of therapies for premature labour
    Higby, K
    Suiter, CR
    [J]. DRUG SAFETY, 1999, 21 (01) : 35 - 56
  • [4] Risk-benefit analysis
    Mossman, KL
    [J]. HEALTH PHYSICS, 2002, 82 (05): : 750 - 750
  • [5] Risk-benefit analysis
    Wilson, R.
    Crouch, E.A.C.
    [J]. Physics Today, 2002, 55 (10)
  • [6] RISK-BENEFIT ANALYSIS
    ZENCEY, M
    [J]. ATLANTIC, 1979, 243 (04): : 37 - 37
  • [7] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [8] Risk-benefit analysis of micronutrients
    Renwick, AG
    Flynn, A
    Fletcher, RJ
    Müller, DJG
    Tuijtelaars, S
    Verhagen, H
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2004, 42 (12) : 1903 - 1922
  • [9] THE FALLACIES OF RISK-BENEFIT ANALYSIS
    SAMUELS, SW
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1979, 329 (OCT) : 267 - 273
  • [10] PENTAMIDINE - A RISK-BENEFIT ANALYSIS
    WISPELWEY, B
    PEARSON, R
    [J]. DRUG SAFETY, 1990, 5 (03) : 212 - 219